-transparent.png){kind=logo}
The possibility of an impaired hepatic de-esterification of enalapril to enalaprilat due to hepatic dysfunction was assessed in seven patients with compensated liver cirrhosis and 10 normal control subjects. The peak serum concentration and time to the peak serum concentration of enalaprilat, as well as the suppression of serum angiotensin converting enzyme activity, following a single oral dose of enalapril maleate (10 mg) were not different in the two groups. The elimination half-life of enalaprilat was related to renal function. The results suggest that hepatic biotransformation of the drug may not be disturbed in a clinically significant manner in patients with moderate hepatic dysfunction due to compensated liver cirrhosis.
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
November 1990,
Arzneimittel-Forschung,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
April 1999,
Clinical therapeutics,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
January 1984,
Acta physiologica Hungarica,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
May 2013,
Digestive diseases and sciences,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
March 2010,
AIDS (London, England),
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
June 1989,
Clinical pharmacology and therapeutics,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
April 1978,
Lancet (London, England),
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
March 1992,
Antimicrobial agents and chemotherapy,
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
June 1982,
Wiadomosci lekarskie (Warsaw, Poland : 1960),
T Baba, and
S Murabayashi, and
T Tomiyama, and
K Takebe
November 1978,
British journal of anaesthesia,
